Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biocon has entered into an option agreement with Bristol-Myers Squibb for its IN-105, an oral insulin drug candidate.
Subscribe to our email newsletter
As part of the agreement, Biocon will conduct clinical studies to further characterize IN-105’s clinical profile till the completion of phase II while Bristol-Myers Squibb will have a global license to IN-105 following the completion of the phase II trial.
Bristol-Myers Squibb will also take up development and commercialization activities outside India upon exercising its license option.
The agreement also provides Biocon with a license fee, regulatory and commercial milestone payments, royalties on commercial sales of IN-105 outside India and rights to IN-105 in India.
Biocon MD and chairman Kiran Mazumdar-Shaw said the agreement helps bringing oral insulin closer to market.
”We are excited to extend the excellent relationship we already enjoy with Bristol-Myers Squibb, and look forward to working closely with them to make this a reality," Mazumdar-Shaw added.